EP300 and head and neck squamous cell carcinoma: Additionally, A-485 led to dramatic and significant repression (ranging from 44% to 75% versus control) of HR in CREBBP or EP300 mutant HNSCC and lung-cancer cell lines, but not in wild-type cells (Fig. 6a) (Supplementary Fig. 6c, d).